跳轉至內容
Merck
  • A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine.

A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine.

Seizure (2005-02-08)
Ewa B Posner, Khalid Mohamed, Anthony G Marson
摘要

To evaluate the role of ethosuximide, sodium valproate and lamotrigine in children and adolescents with typical absence seizures (AS). A systematic review of randomized controlled trials that included children or adolescents with typical absence seizures who received treatment with ethosuximide, sodium valproate or lamotrigine. Four RCTs fulfilled the inclusion criteria. Due to the heterogeneity of the studies the results could not be pooled in a meta-analysis. We found no reliable evidence to inform clinical practice. The design of further trials should be pragmatic and compare one drug with another.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
乙琥胺
Supelco
乙琥胺, Pharmaceutical Secondary Standard; Certified Reference Material
乙琥胺, European Pharmacopoeia (EP) Reference Standard